Autoantigen mRNA-LNP Vaccination Drives Therapeutic Efficacy in Preclinical Models for Autoimmunity
Paulien Baeten1,2, Karen Beets3, Tessa Schalley1,2
1University MS Center, Campus Diepenbeek, Diepenbeek, Belgium.
Summary
Messenger RNA (mRNA) lipid nanoparticles (LNPs) encoding autoantigens can treat autoimmune diseases like multiple sclerosis (MS) and type 1 diabetes (T1D) by re-establishing immune tolerance, challenging previous assumptions about vaccine design.
Area of Science:
- Immunology
- Vaccinology
- Nanotechnology
Background:
- Autoimmune diseases (e.g., MS, T1D) lack therapies for durable, antigen-specific immune tolerance.
- Current mRNA vaccines often induce immune activation, not tolerance.
Purpose of the Study:
- To investigate if mRNA-LNPs encoding autoantigens can induce immune tolerance and treat autoimmune diseases.
- To explore the mechanisms behind mRNA-LNP-mediated immune modulation.
Main Methods:
- Delivery of MOG27-63 mRNA-loaded LNPs in experimental autoimmune encephalomyelitis (EAE) and T1D models.
- Analysis of APC and CD4+ T cell phenotypes.
- Co-delivery of immunoregulatory mRNAs (IL-2 mutein, CCL1) with autoantigen mRNA.
Main Results:
- mRNA-LNPs attenuated disease severity in EAE and T1D models, demonstrating antigen-specific protection.
- Therapeutic efficacy was achieved with immunostimulatory LNPs, contrary to expectations.
- LNPs targeted APCs, promoting homeostasis and CD4+ T cell hyporesponsiveness without inducing Tregs.
- Co-delivery with immunoregulatory mRNAs enhanced clinical outcomes.
Conclusions:
- Autoantigen mRNA-LNPs represent a promising strategy for antigen-specific immunotherapy in autoimmune diseases.
- mRNA-LNP therapy can be tailored to induce immune tolerance, not just activation.
- Combined delivery of autoantigen and immunoregulatory mRNAs offers enhanced therapeutic potential.
